9.49
-0.23(-2.37%)
Currency In USD
| Previous Close | 9.72 |
| Open | 9.7 |
| Day High | 10.13 |
| Day Low | 9.46 |
| 52-Week High | 15.47 |
| 52-Week Low | 8.06 |
| Volume | 70,833 |
| Average Volume | 64,878 |
| Market Cap | 129.35M |
| PE | -6.93 |
| EPS | -1.37 |
| Moving Average 50 Days | 11.23 |
| Moving Average 200 Days | 10.94 |
| Change | -0.23 |
If you invested $1000 in Greenwich LifeSciences, Inc. (GLSI) since IPO date, it would be worth $1,898 as of October 19, 2025 at a share price of $9.49. Whereas If you bought $1000 worth of Greenwich LifeSciences, Inc. (GLSI) shares 3 years ago, it would be worth $988.54 as of October 19, 2025 at a share price of $9.49.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Greenwich LifeSciences Announces Addition of Austria to Flamingo-01 Clinical Trial
GlobeNewswire Inc.
Oct 09, 2025 10:00 AM GMT
STAFFORD, Texas, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immuno
Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Belgium
GlobeNewswire Inc.
Oct 02, 2025 10:00 AM GMT
STAFFORD, Texas, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immuno
Greenwich LifeSciences Announces Addition of Portugal to Flamingo-01 Clinical Trial
GlobeNewswire Inc.
Sep 30, 2025 10:00 AM GMT
STAFFORD, Texas, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immun